X

Trial Profile

An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ORIC 101 (Primary) ; Paclitaxel (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Testicular cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Sponsors ORIC Pharmaceuticals

Most Recent Events

11 Dec 2023 Status changed from active, no longer recruiting to discontinued.
22 Sep 2022 Planned End Date changed from 1 May 2022 to 1 Jun 2023.
22 Sep 2022 Planned primary completion date changed from 1 May 2022 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com